Leukos Biotech is a dynamic spin-off company from the Josep Carreras Leukaemia Research Institute, dedicated to advancing groundbreaking treatments and diagnostic tools for a wide range of tumors. Whether it's hematological or solid tumors, our ultimate goal is to revolutionize cancer care. At Leukos Biotech, we have discovered a promising new oncological target called the serotonin receptor 1B (HTR1B).

This receptor shows remarkable selectivity for cancer stem cells and chemotherapy-resistant cancer cells, making it an attractive focus for pharmacological intervention. Through intensive research and development, we have developed a diverse portfolio of molecules specifically designed to target HTR1B. Our leading candidate, LB208, is a game-changing, orally available NCE (New Chemical Entity) that acts as a highly specific and selective HTR1B antagonist.

Not only does it demonstrate powerful and broad-spectrum antitumoral activity, but it also comes with a favorable safety profile. LB208 holds immense potential in addressing the urgent needs of patients with solid tumors like Triple Negative Breast Cancer (TNBC), Hepatocellular Carcinoma (HCC), and Ovarian Cancer, as well as hematological malignancies like Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). By selectively targeting cancer stem cells and resistant cells, LB208 induces apoptosis and terminal differentiation while sparing healthy cells.

This innovative mechanism of action not only provides short-term benefits by eliminating resistant cells but also offers long-term potential by targeting the stem cell reservoir and minimizing the risk of relapse. In collaboration with AOP Health, Leukos Biotech is ready to take LB208 to the next level of development, paving the way for transformative therapies in oncology and beyond. We are also proud to have validated proprietary monoclonal antibodies (mAbs) as biomarkers for cancer diagnosis and prognosis based on the expression of the target.

With our cutting-edge research, passionate team, and dedicated partners and investors, Leukos Biotech is poised to create a future where cancer is no longer an insurmountable challenge. Contact us to join our mission and make a meaningful impact on patients' lives